CN-122006052-A - Gas washout vent for patient interface

Abstract

A gas washout vent includes a housing having a first wall with one or more channels therethrough configured to be in fluid communication with a portion of a patient interface system exposed to therapeutic pressure. The channels include respective first openings on the first surface of the first wall. The housing at least partially defines a second opening in communication with the ambient atmosphere. The diffusing material is at least partially located within the housing to be adjacent to the first surface. The surface of the diffusing material facing the first surface is spaced from the first surface by a gap that extends to provide fluid communication between all of the first openings and between all of the first and second openings. The housing is configured such that air is prevented from flowing out of the housing at all areas directly opposite each of the first openings.

Inventors

• T.H.Zhou
• M.P. Dantanayana
• R. Keira
• D.M. Maurier
• M.L.Di

Assignees

• 瑞思迈私人有限公司

Dates

Publication Date

20260512

Application Date

20171109

Priority Date

20161111

Claims (20)

1. 1. A gas washout vent for a patient interface system configured to maintain a therapeutic pressure in a range of about 4cmH 2 O to about 30cmH 2 O above ambient pressure during an entire patient's respiratory cycle when the patient is sleeping to improve respiratory or sleep disordered breathing conditions, the gas washout vent comprising: A housing including a first wall having one or more channels therethrough configured to be in fluid communication with a portion of the patient interface system configured to be exposed to the therapeutic pressure, the channels including respective first openings on a first surface of the first wall, the housing at least partially defining a second opening in communication with an ambient atmosphere, and A diffusing material at least partially within the housing to be adjacent to the first surface, a surface of the diffusing material facing the first surface being spaced from the first surface by a gap extending to provide fluid communication between all of the first openings and the second openings; wherein the housing is configured such that air is prevented from flowing out of the housing at all areas directly opposite each of the first openings.
2. 2. The gas washout vent according to claim 1, wherein the housing further comprises a third opening in communication with ambient atmosphere, wherein the third opening does not overlap with an outlet region of any channel protruding along a central axis of the respective channel, and is positioned such that at least a portion of the diffusing material is located between each first opening and the third opening.
3. 3. The gas washout vent according to claim 2, wherein the third opening is oriented such that a central axis through the third opening is angled with respect to a central axis of any channel.
4. 4. A gas washout vent according to claim 2 or 3, wherein the third opening is dimensioned such that complete obstruction of the third opening does not significantly reduce gas flow through the gas washout vent when a portion of the patient interface is exposed to the therapeutic pressure.
5. 5. The gas washout vent according to claim 4, wherein gas flow through the gas washout vent is not reduced by more than three percent.
6. 6. The gas washout vent according to any one of claims 2 to 5, wherein the third opening is one of a number of third openings.
7. 7. The gas washout vent according to any one of claims 2 to 6, wherein the third opening is configured to remove water.
8. 8. The gas washout vent according to any one of claims 1 to 6, wherein the second openings comprise a number of second openings.
9. 9. The gas washout vent according to any one of claims 1 to 8, wherein at least one of the one or more channels is sized such that at least a portion of air exiting the respective first opening permeates into the diffusing material when a portion of the patient interface is exposed to the therapeutic pressure.
10. 10. The gas washout vent according to claim 9, wherein the gas washout vent is configured such that a portion of the air permeated into the diffusing material exits the diffusing material and re-enters the gap before exiting from the second opening.
11. 11. The gas washout vent according to one of claims 9 or 10, wherein the gas washout vent is configured such that a portion of the air exiting the respective first opening permeates through the surface and exits the diffusing material.
12. 12. The gas washout vent according to any one of claims 1 to 11, wherein no more than 28dB (a) of noise is generated as a result of a portion of the patient interface being exposed to the therapeutic pressure when air exits the second opening.
13. 13. The gas washout vent according to any one of claims 1 to 12, wherein the diffusing material comprises uncompressed fibers.
14. 14. The gas washout vent according to any one of claims 1 to 12, wherein the diffusing material comprises a hygroscopic material.
15. 15. The gas washout vent according to claim 14, wherein the hygroscopic material is sintered plastic.
16. 16. The gas washout vent according to any one of claims 1 to 12, wherein the diffusing material comprises a hydrophobic material.
17. 17. The gas washout vent according to any one of claims 1 to 16, wherein the diffusing material has antibacterial properties.
18. 18. The gas washout vent according to any one of claims 1 to 17, wherein the first wall is non-releasably secured within the housing.
19. 19. The gas washout vent according to any one of claims 1 to 18, wherein the gap is at least partially defined by the first wall from a first opening to the second opening.
20. 20. The gas washout vent according to claim 19, wherein the gap is formed by a surface of a portion of the diffusing material from a location opposite the first opening to closest to the second opening.

Description

Gas washout vent for patient interface The present application is a divisional application of patent application number 202210128752.0, application date 2017, 11, 9, and entitled "gas washout vent for patient interface", while patent application number 202210128752.0 is a divisional application of patent application number 201780079694.4, application date 2017, 11, 9, and entitled "gas washout vent for patient interface". The application claims the benefit of U.S. provisional application No. 62/420,678, filed 11/2016, 11, the entire contents of which are incorporated herein by reference. Background 1.1 Technical field The present technology relates to one or more of detection, diagnosis, treatment, prevention and amelioration of respiratory related disorders. The present technology also relates to medical devices or apparatus and uses thereof. 1.2 Description of related Art 1.2.1 Human respiratory system and disorders thereof The respiratory system of the human body promotes gas exchange. The nose and mouth form the entrance to the airway of the patient. The airways include a series of branch airways that become narrower, shorter and more numerous as they penetrate deeper into the lungs. The main function of the lungs is gas exchange, allowing oxygen from the inhaled air to enter venous blood and to expel carbon dioxide in the opposite direction. The trachea is divided into left and right main bronchi, which are ultimately subdivided into terminal bronchioles. The bronchi constitute the conducting airways, but do not participate in gas exchange. The other branches of the airway lead to the respiratory bronchioles and ultimately to the alveoli. The alveolar region of the lung is the region where gas exchange occurs and is referred to as the respiratory region. See, respiratory physiology (Respiratory Physiology), 9 th edition published by John b.west, lippincott Williams & Wilkins in 2012. There are a range of respiratory disorders. Certain disorders may be characterized by specific events such as apneas, hypopneas, and hyperapneas. Examples of respiratory disorders include Obstructive Sleep Apnea (OSA), tidal breathing (CSR), respiratory insufficiency, obesity Hyperventilation Syndrome (OHS), chronic Obstructive Pulmonary Disease (COPD), neuromuscular disease (NMD), and chest wall disorders. Obstructive Sleep Apnea (OSA) SLEEP APNEA) is a form of sleep disordered breathing (SDB, sleep Disordered Breathing) characterized by events that include occlusion or blockage of the upper airway during sleep. It results from the combination of abnormally small upper airway and normal loss of muscle tone in the tongue, soft palate, and area of the posterior oropharyngeal wall during sleep. This condition causes the affected patient to stop breathing, typically for a period of 30 seconds to 120 seconds, sometimes 200 to 300 times per night. This often results in excessive daytime sleepiness, and can lead to cardiovascular disease and brain damage. The complications are common disorders, especially in middle-aged overweight men, but the affected person may not be aware of the problem. See U.S. Pat. No.4,944,310 (Sullivan). Tidal breathing (CSR) is another form of sleep disordered breathing. CSR is an obstacle to the respiratory controller of a patient in which there are alternating periods of rhythms called the dominant and declining ventilation of the CSR cycle. CSR is characterized by repeated hypoxia and reoxygenation that causes arterial blood. CSR may be detrimental due to insufficient repetitive oxygen. In some patients, CSR is associated with repetitive arousal from sleep, which results in severe sleep disruption, increased sympathetic activity, and increased afterload. See U.S. Pat. No. 6,532,959 (Berthon-Jones). Respiratory failure is a covered term for respiratory disorders in which the lungs cannot inhale enough oxygen or exhale enough CO 2 to meet the needs of the patient. Respiratory failure may include some or all of the following disorders. Patients with respiratory insufficiency, a form of respiratory failure, can experience abnormal shortness of breath while exercising. Obesity hyperventilation syndrome (OHS, obesity Hyperventilation Syndrome) is defined as a combination of severe obesity and chronic hypercapnia upon waking, among other known causes of hypoventilation. Symptoms include dyspnea, morning headaches, and excessive daytime sleepiness. Chronic obstructive pulmonary disease (COPD, chronic Obstructive Pulmonary Disease) includes any one of a group of lower airway diseases that share some common features. These include increased airflow resistance, prolonged expiratory phases of breathing, and loss of normal elasticity of the lungs. Examples of COPD are emphysema and chronic bronchitis. COPD is caused by chronic smoking (major risk factor), occupational exposure, air pollution and genetic factors. Symptoms include dyspnea during exercise, chronic cough, and sputum production. Neuromuscular disease